Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 2/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 7/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1776054 | 1.00 | GJB2 (0.42) | GJB2PTPN1PTPN2PTPN11SLC6A2 | |
| SCHEMBL1775581 | 0.92 | PTPN1 (0.48) | GJB2PTPN1PTPN2PTPN11NT5E | |
| SCHEMBL1775584 | 0.92 | PTPN1 (0.48) | GJB2PTPN1PTPN2PTPN11NT5E | |
| SCHEMBL1778351 | 0.92 | PTPN1 (0.46) | GJB2PTPN1PTPN2PTPN11NT5E | |
| SCHEMBL1776055 | 0.92 | PTPN1 (0.46) | GJB2PTPN1PTPN2PTPN11NT5E | |
| SCHEMBL2920412 | 0.88 | PTPN1 (0.43) | GJB2PTPN1PTPN2PTPN11NT5E | |
| SCHEMBL1776279 | 0.88 | PTPN1 (0.43) | GJB2PTPN1PTPN2PTPN11NT5E | |
| SCHEMBL5568194 | 0.88 | PTPN1 (0.43) | GJB2PTPN1PTPN2PTPN11NT5E | |
| SCHEMBL1776183 | 0.88 | PTPN1 (0.45) | GJB2PTPN1PTPN2PTPN11NT5E | |
| SCHEMBL1775852 | 0.88 | PTPN1 (0.46) | GJB2PTPN1PTPN2PTPN11NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7943584-B2 | Medicinal composition containing diabetes remedy | SANKYO COMPANY, LIMITED (JP) | 2011-05-17 | — | — | US | disclosed |
| EP-1589023-B1 | OLIGOSACCHARIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7632930-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2009-12-15 | — | — | US | disclosed |
| US-20080194495-A1 | Oligosaccharide Derivative | HONDA TAKESHI | 2008-08-14 | — | — | US | disclosed |
| US-7361744-B2 | Oligosaccharide derivative | SANKYO COMPANY LIMITED (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | SANKYO COMPANY, LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1792620-A1 | MEDICINAL COMPOSITION CONTAINING DIABETES REMEDY | Sankyo Company, Limited (JP) | 2007-06-06 | — | — | EP | disclosed |
| US-20060025350-A1 | Oligosaccharide derivative | SANKYO COMPANY, LIMITED (JP) | 2006-02-02 | — | — | US | disclosed |
| EP-1589023-A1 | OLIGOSACCHARIDE DERIVATIVE | Sankyo Company, Limited (JP) | 2005-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039367-A1 | Medicinal Composition Containing Diabeted Remedy | DPP4, IAPP, AMY2A | GJB2 4641/4885PTPN1 175/4885PTPN2 343/4885 |
| US-20060025350-A1 | Oligosaccharide derivative | MAN1B1, FUT6, MAN2A1 | GJB2 4783/4885PTPN1 1359/4885PTPN2 1866/4885 |
| US-20080194495-A1 | Oligosaccharide Derivative | MAN1B1, FUT6, MAN2A1 | GJB2 4783/4885PTPN1 1359/4885PTPN2 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.